logo
Plus   Neg
Share
Email

Seattle Genetics, Astellas, Merck To Evaluate Enfortumab Vedotin Plus KEYTRUDA

Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. have entered a clinical collaboration agreement with Merck to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA, in patients with previously untreated metastatic urothelial cancer. The companies will conduct a global, registrational phase 3 clinical trial to be led by Seattle Genetics. The companies currently plan to initiate the trial in the first half of 2020.

Enfortumab vedotin is currently under review by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The PDUFA action date is March 15, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PCNA has recalled about 5,000 units of Spare 10,000 mAh Power Banks for possible fire and burn hazards, the U.S. Consumer Product Safety Commission said in a statement. These include 445 units sold in Canada. The company said the power bank's lithium-ion battery can overheat and ignite, causing fire and burn hazards. Hundreds of Amazon workers have openly criticized the company's record on climate change by intentionally defying a company-wide ban against speaking out. More than 350 employees of the e-commerce giant criticized the company's climate change policy in a Medium blog post Sunday, putting their jobs at risk for violating the company's corporate communications policy. Loneliness at the workplace is on the rise in America and is resulting in less productivity as well as lower retention levels, a new study showed. According to Cigna's 2020 Loneliness Index, three out of five adults, or 61 percent, consider themselves lonely. This represents a seven percentage point increase from 2018. The study surveyed more than 10,400 adults.
Follow RTT
>